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After the publication of the original article \[[@CR1]\], it came to the authors' attention that there was an error in the originally published version of Fig. [5](#Fig1){ref-type="fig"}b. The image of CD4^+^CD25^+^ T cells of the statin-Dex group was unintentionally replaced with the image of CD4^+^CD25^+^ T cells from the control group. The correct version of Fig. [5](#Fig1){ref-type="fig"}b is published in this Erratum.Fig. 5Statin-Dex treatment increase the number of CD4^+^Foxp3^+^ T cells in lymphocytes. Expressions of CD4^+^CD25^+^ T cells and CD4^+^Foxp3^+^ T cells among lymph node MNC in statin-Dex group, control-Dex group, and control group were detected by FACS. The results showed that statin-Dex treatment increased the percentage of CD4^+^Foxp3^+^ T cells among lymph node MNC when compared with control-Dex and PBS treatments, while there was no difference for the percentage of CD4^+^CD25^+^ T cells. Meanwhile, we did not observe difference in the percentages of CD4^+^CD25^+^ T cells and CD4^+^Foxp3^+^ T cells between control-Dex group and control group (**a**, **b**). The results are expressed as mean ± SD (*n* = 5 rats per group) (\**p* \< 0.05)
